The Recall Desk
SevereFDA (Drugs)·D-0245-2021·Announced 2021-02-03

Fresenius Kabi Recalls Ketorolac Tromethamine Injection Due to Particulate Matter

Fresenius Kabi is recalling specific vials of Ketorolac Tromethamine Injection because particulate matter was found in reserve samples.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: The agency classification is FDA Class I, which mandates a minimum severity score of 4 according to the rubric.

Plain-English summary

Fresenius Kabi USA, LLC is recalling 945,425 vials of Ketorolac Tromethamine Injection, USP, 30 mg per mL. The affected product is packaged in 1 mL Single Dose Vials and is intended for intramuscular or intravenous use. The recall covers Lot # 6121083, which has an expiration date of 2/2021.

The recall was initiated because particulate matter was found in reserve sample vials at the firm. The affected product was distributed nationwide in the United States and Puerto Rico.

Healthcare providers and patients should stop using the affected vials and contact their healthcare provider or the manufacturer for further instructions.

The recalled product

Product
KETOROLAC TROMETHAMINE (KETOROLAC TROMETHAMINE)
Brand
KETOROLAC TROMETHAMINE
Affected units
945,425

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot # 6121083
  • Exp 2/2021

UPCs (4)

  • 0363323162115
  • 0363323161002
  • 0363323162009
  • 0363323162030

Distribution

Distributed nationwide across the United States.

The notice also names 1 state specifically:

Same manufacturer · Fresenius Kabi USA, LLC

See all →